Rekomendatsii AASLD po lecheniyu nealkogol'noy zhirovoy bolezni pecheni. Vozmozhnost' ispol'zovaniya v Rossii


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Growth in the number of overweight people around the world maintains an interest in the diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD). Output in 2012 the American College of Gastroenterology Management (American College of Gastroenterology - ACG) and the American Association of Gastroenterology (American Gastroenterological Association - AGA) for the diagnosis and management of patients with NAFLD (Manual ACG / AGA) can largely facilitate the work of medical practitioners. This publication is devoted to a brief overview.

Full Text

Restricted Access

References

  1. Chalasani N., Younossi Z., Lavine J.E., et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am. J. Gastroenterol. 2012; 107: 811-26
  2. Пиманов С.И. Американские рекомендации по диагностике и лечению неалкогольной жировой болезни печени: кое- что проясняется. Cons. Med. Гастроэнтерология. 2012; 2: 80-5.
  3. Ratziu V., de Ledinghen V., Oberti F., et al. Arandomized controlled trial of high-dose Ursodeoxycholic acid for non-alcoholic steatohepatitis. J. Hepatol. 2011; 13(5): 1011-9. doi: 10.1016/j.jhep. 2010.08.030.
  4. Kidd P.M. Cell membranes, endothelia, and atherosclerosis the importance of Phosphatidylcholine. Altern. Med. Rev. 1996; 1: 148-67.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies